Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcturus Therapeutics Holdings (ARCT) Cash & Current Investments (2018 - 2025)

Historic Cash & Current Investments for Arcturus Therapeutics Holdings (ARCT) over the last 8 years, with Q3 2025 value amounting to $235.4 million.

  • Arcturus Therapeutics Holdings' Cash & Current Investments fell 1944.64% to $235.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $235.4 million, marking a year-over-year decrease of 1944.64%. This contributed to the annual value of $292.0 million for FY2024, which is 1629.8% down from last year.
  • According to the latest figures from Q3 2025, Arcturus Therapeutics Holdings' Cash & Current Investments is $235.4 million, which was down 1944.64% from $251.5 million recorded in Q2 2025.
  • Over the past 5 years, Arcturus Therapeutics Holdings' Cash & Current Investments peaked at $466.8 million during Q1 2021, and registered a low of $235.4 million during Q3 2025.
  • For the 5-year period, Arcturus Therapeutics Holdings' Cash & Current Investments averaged around $327.1 million, with its median value being $319.7 million (2022).
  • As far as peak fluctuations go, Arcturus Therapeutics Holdings' Cash & Current Investments surged by 68498.6% in 2021, and later tumbled by 4257.37% in 2022.
  • Arcturus Therapeutics Holdings' Cash & Current Investments (Quarter) stood at $370.5 million in 2021, then increased by 5.77% to $391.9 million in 2022, then fell by 10.97% to $348.9 million in 2023, then fell by 16.3% to $292.0 million in 2024, then decreased by 19.4% to $235.4 million in 2025.
  • Its Cash & Current Investments stands at $235.4 million for Q3 2025, versus $251.5 million for Q2 2025 and $255.4 million for Q1 2025.